PORTLAND, Ore., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the initiation of the Company's Institutional Review Board (IRB)-approved cancer patient registry study entitled RELIEF: Rapid Evaluation of Lifestyle, Independence, and Elimination of breakthrough cancer pain with Freedom from oral discomfort through the use of Abstral® (fentanyl) Sublingual Tablets. RELIEF is a post-marketing multicenter trial to assess Abstral for breakthrough cancer pain (BTcP) in opioid-tolerant cancer patients. Abstral is available to patients and health care professionals at pharmacies nationwide, and recruitment and enrollment for the registry trial is underway.
Help employers find you! Check out all the jobs and post your resume.
